Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX -15.38% 3-Year Share Buyback Ratio is -159.10 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 172 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 96.51% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Imagion Biosystems's current 3-Year Share Buyback Ratio was -159.10%.
The historical rank and industry rank for Imagion Biosystems's 3-Year Share Buyback Ratio or its related term are showing as below:
ASX:IBX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -159.1 Med: -54.3 Max: -9.4
Current: -159.1
During the past 9 years, Imagion Biosystems's highest 3-Year Share Buyback Ratio was -9.40%. The lowest was -159.10%. And the median was -54.30%.
ASX:IBX's 3-Year Share Buyback Ratio is ranked worse than 96.51% of 172
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.5
vs ASX:IBX: -159.10
Imagion Biosystems (ASX:IBX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Imagion Biosystems 3-Year Share Buyback Ratio Related Terms
ASX:IBX vs TMO, DHR, IDXX: 3-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems 3-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's 3-Year Share Buyback Ratio falls into.
Imagion Biosystems 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -159.10 mean?
Imagion Biosystems (ASX:IBX) has a 3-Year Share Buyback Ratio of -159.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #166 out of 172 companies in the Medical Diagnostics & Research industry, placing it in the top 96.5%.
Is Imagion Biosystems' 3-Year Share Buyback Ratio too high?
Imagion Biosystems' current 3-Year Share Buyback Ratio is -159.10. Based on the distribution chart, Imagion Biosystems ranks #166 out of 172 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' 3-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #166 out of 172 companies for 3-Year Share Buyback Ratio. This places Imagion Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Imagion Biosystems and its competitors. Imagion Biosystems's current 3-Year Share Buyback Ratio is -159.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 99% below its estimated fair value. The current 3-Year Share Buyback Ratio is -159.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current 3-Year Share Buyback Ratio is -159.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
